Novo Nordisk Hit With Antitrust Action Over Prandin

Law360, New York (June 1, 2010, 1:27 PM EDT) -- Novo Nordisk A/S has been slapped with a putative class action that accuses it of attempting to monopolize the market for popular diabetes treatment Prandin by pursuing sham infringement litigation against generic-drug makers.

American Sales Co. Inc., which purchases health products and prescription drugs for retail stores, filed the complaint Friday in the U.S. District Court for the Eastern District of Michigan.

The suit claims that Novo Nordisk has maintained an unlawful monopoly on the market for repaglinide — sold under the brand name Prandin in...
To view the full article, register now.